Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Position Increased by Jane Street Group LLC

Jane Street Group LLC lifted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 245.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 401,908 shares of the biopharmaceutical company’s stock after buying an additional 285,564 shares during the quarter. Jane Street Group LLC’s holdings in Catalyst Pharmaceuticals were worth $7,990,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of CPRX. Susquehanna Fundamental Investments LLC bought a new position in Catalyst Pharmaceuticals in the second quarter worth about $258,000. Integral Health Asset Management LLC bought a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth approximately $4,260,000. GSA Capital Partners LLP acquired a new position in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $625,000. Capstone Investment Advisors LLC bought a new position in Catalyst Pharmaceuticals during the 3rd quarter worth $708,000. Finally, Allspring Global Investments Holdings LLC increased its position in Catalyst Pharmaceuticals by 146.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company’s stock worth $7,285,000 after buying an additional 217,956 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Stephens assumed coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 price target for the company. Truist Financial upped their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $31.14.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the sale, the insider now directly owns 51,391 shares in the company, valued at approximately $1,167,603.52. The trade was a 18.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the transaction, the insider now owns 686,996 shares of the company’s stock, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 79,500 shares of company stock worth $1,754,140 over the last ninety days. Company insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Trading Up 0.2 %

Shares of NASDAQ:CPRX opened at $21.38 on Friday. The company has a 50 day moving average of $21.62 and a 200-day moving average of $19.14. The firm has a market cap of $2.55 billion, a P/E ratio of 18.12, a P/E/G ratio of 3.35 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a twelve month low of $13.12 and a twelve month high of $24.27.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.